在COVID-19中的经验性阿齐思罗米会影响呼吸道微生物组和抗菌药物抵抗性,但没有抗炎功效
Charles Langelier1, Abigail Glascock2, Cole Maguire3
1University of California, San Francisco.
Research square
|June 30, 2025
概括
在COVID-19患者中使用阿齐思罗米会破坏鼻腔微生物群,增加真菌和病原性细菌. 它还提高了抗微生物耐药性基因,但没有提供抗炎作用.
科学领域:
- 微生物学 微生物学
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 阿齐思罗米经常被用于呼吸道感染,包括在COVID-19大流行期间,尽管对病毒性疾病缺乏已证明的益处.
- 阿齐思罗米对SARS-CoV-2患者呼吸道微生物群和抗菌素耐药性的影响尚不完全理解.
研究的目的:
- 研究阿齐思罗米对入院COVID-19患者鼻腔微生物群,抗菌素抗性和宿主免疫反应的影响.
主要方法:
- 一项前性多中心队列研究,涉及1164名因SARS-CoV-2感染住院的患者.
- 长度鼻子转录组学被用来比较接受阿齐思罗米,其他抗生素或没有抗生素的患者.
- 通过外周血液和上呼吸道转录组分析来评估宿主免疫反应.
主要成果:
- 阿齐思罗米治疗改变了鼻子微生物组合,减少了细菌和增加了真菌的相对丰富性,以及可能致病的种类,如克莱布西拉和葡萄球菌.
- 在暴露于阿齐思罗米辛后,观察到抗菌素耐药性基因的显著增加,可在一天内检测到.
- 特定的MLS耐药基因 (ermC,msrA,ermX) 的表达显著增加,与开始性和致病性细菌的丰富程度相关.
- 在宿主免疫反应中没有发现炎症基因表达的显著差异.
结论:
- 在COVID-19患者中,阿兹罗米辛治疗会诱导上呼吸道微生物组失调,并改变MLS抗菌素耐药性基因表达.
- 这些变化发生在对宿主免疫系统没有任何明显的抗炎作用的情况下.
相关概念视频
01:28Antimicrobial Effectiveness
175
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
175
01:17Drugs Used in Lower Respiratory Disorders: Overview
618
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
618
01:19Antiasthma Drugs: Leukotriene Modifiers
495
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
495
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
476
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
476